Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)

European Journal of Cancer

Volumn 48, Issue 16, 2012, Pages 2993-3000

  Meulenbeld, H J ^a   Van Werkhoven, E D ^b   Coenen, J L L M ^c   Creemers, G J ^d   Loosveld, O J L ^e   De Jong, P C ^f   Ten Tije, A J ^e,g   Fossa S D ^h   Polee, M ⁱ   Gerritsen, W ^j   Dalesio, O ^b   De Wit, R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Isala Klinieken ^*  (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e AMPHIA HOSPITAL   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g TERGOOI HOSPITAL   (Netherlands)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ MEDICAL CENTER LEEUWARDEN   (Netherlands)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Bisphosphonates; Bone metastases; Castration Resistant Prostate Cancer; Docetaxel; Risedronate

Indexed keywords

DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CASTRATION; DISEASE PROGRESSION; ETIDRONIC ACID; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NETHERLANDS; NORWAY; PAIN; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867571938     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.05.014     Document Type: Article

References (26)

1. F. Saad, and A. Lipton Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease Semin Oncol 34 Suppl. 4 2007 S17 S23
2. F. Saad, D.M. Gleason, and R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
3. A. Berruti, L. Dogliotti, and M. Tucci Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates J Urol 166 2001 2023 2031
4. N.W. Clarke, J. McClure, and N.J. George Morphometric evidence for bone resorption and replacement in prostate cancer Br J Urol 68 1991 74 80
5. F. Saad, N. Clarke, and M. Colombel Natural history and treatment of bone complications in prostate cancer Eur Urol 49 2006 429 440
6. A. Berruti, L. Dogliotti, and R. Bitossi Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline J Urol 164 2000 1248 1253
7. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 95 2003 879 882
8. F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
9. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
10. G. Morgan, and A. Lipton Antitumor effects and anticancer applications of bisphosphonates Semin Oncol 37 Suppl. 2 2010 S30 S40
11. T. Powles, S. Paterson, and J.A. Kanis Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 2002 3219 3224
12. R.E. Coleman, M.C. Winter, and D. Cameron The effects of adding zoledronic acid to neoadjuvant chemotherapy in tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 2010 1099 2005
13. S. Boissier, M. Ferreras, and O. Peyruchaud Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 11 2000 2949 2954
14. M.V. Lee, E.M. Fong, and F.R. Singer Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 61 6 2001 2602 2608
15. C.J. Dunn, and K.L. Goa Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease Drugs 61 2001 685 712
16. E.R. van Beek, C.W. Lowik, and J. van Wijngaarden Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease Breast Cancer Res Treat 118 2 2009 Nov 307 313
17. B. Karabulut, C. Erten, and M.K. Gul Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells Cell Biol Int 33 2009 239 246
18. K.D. Brubaker, L.G. Brown, and R.L. Vessella Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment BMC Cancer 6 2006 15
19. A. Ullen, L. Lennartsson, and U. Harmenberg Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid Acta Oncol 44 2005 644 650
20. R. Melzack The McGill pain questionnaire: major properties and scoring methods Pain 1 1975 277 299
21. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
22. H.I. Scher, S. Halabi, and F. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
23. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
24. A. Sasaki, B.F. Boyse, and B. Story Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice Cancer Res 55 1995 3551 3557
25. D.P. Dearnaley, M.D. Mason, M.K. Parmar, K. Sanders, and M.R. Sydes Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872 876
26. F. Saad, and M. Colombel Management of castration resistant prostate cancer bisphosphonates and emerging therapies Expert Rev Anticancer Ther 10 2010 1991 2002